Navigation Links
Miltenyi Biotec GmbH Acquires Medic Tools AG
Date:6/10/2008

BERGISCH GLADBACH, Germany, June 10 /PRNewswire/ -- Miltenyi Biotec has acquired Medic Tools AG from Zug, Switzerland. With this acquisition, Miltenyi Biotec strengthens the portfolio in the area of sample preparation. "The innovative and high-quality devices and techniques fit perfectly into the product range of instruments, reagents, and services offered by Miltenyi Biotec", Miltenyi Biotec CEO Dr. Boris Stoffel and Franz G. Bucher, Vice President and CEO of Medic Tools AG, stated in a conjoint announcement.

As a first result of the previous cooperation, the gentleMACS(TM) Dissociator was introduced into the market several months ago. The instrument facilitates the generation of single-cell suspensions from tissues and thus, helps generate the ideal starting material for the separation and isolation of specific cell types using MACS(R) Technology. This procedure to separate cells magnetically was developed by Miltenyi Biotec and is a research laboratory standard worldwide.

The additional expertise of Medic Tools enables Miltenyi Biotec to further engage in development projects in the area of sample preparation. "We offer our biomedical research customers a complete solution", adds Dr. Stoffel, "from sample preparation to cell separation, cell analysis, cytological and molecular analysis."

The involved parties agreed that financial details of the transaction should not be disclosed.

About Miltenyi Biotec

The company is one of the largest and most successful biotechnology companies in Germany. More than 1,100 employees develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.

Contact:

Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH

Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany

Phone +49-2204-8306-6590, E-mail uweh@miltenyibiotec.de

http://www.miltenyibiotec.com


'/>"/>
SOURCE Miltenyi Biotec GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
2. Brazils biotech firms: From imitators to innovators in health-related products
3. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
4. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
5. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
6. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
7. Hologic to Present at the Needham Seventh Annual Biotechnology and Medical Technology Conference
8. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
11. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. Ltd. ... KRW (US $18.9M) Series A financing. This financing round ... Tech Venture and SNU Bio Angel. This new funding ... billion KRW (US $27.7M) since its founding in 2015. ... bolster the development and commercialization of its immuno-oncology programs, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
Breaking Biology News(10 mins):